

PrCLOZARIL® Support and Assistance Network (CSAN®)

OVER 30 YEARS

Committed to optimizing hematological monitoring for your patients through innovation.

*The longest-running clozapine patient support program in Canada.*¹*

Promoting complementary support for healthcare professionals:

With the CSAN® program, we aim to offer a wide range of value-added services for CLOZARIL®-treated patients and their families.

STRIVING
TO GO BEYOND
WITH OUR
SERVICE OFFERINGS

CLOZARIL® (clozapine) tablet is indicated in the management of symptoms of treatment-resistant schizophrenia.²

Please consult the CLOZARIL® Product Monograph at http://www.hlstherapeutics.com/wp-content/uploads/monograph_pdf/HLS-Clozaril-PM-E.pdf for important information on contraindications, warnings, precautions, adverse reactions, drug interactions, dosing, and conditions of clinical use.

The Product Monograph is also available by calling 1-800-267-2726.

*Comparative clinical significance is unknown.




Tailored services supported by a team of experts to help optimize patient management

Our team of experts



An extensive team of dedicated professionals who offer a proactive service designed to:

- support CLOZARIL[®]-treated patients with hematological testing compliance monitoring³
- provide close follow-up of high-risk patients



Access to **bilingual specialty consultants** who can help guide a unique course of action throughout your patient's CLOZARIL[®] treatment journey:

- psychiatrists, cardiologists, registered nurse educators, a hematologist, and a nutritionist



Supporting you **24/7/365** (including holidays) with any required assistance – including use of the CSAN Patient Care Portal[®]



Full-time bilingual Patient Support Program coordinators and nurse educators who are assigned in tandem to a specific institution

Striving to go beyond with our extensive resources

CSAN® services include:



Proactive and customized follow-up on hematological testing and monitoring, to facilitate the appropriate dispensing and safe use of CLOZARIL®



Personalized treatment team services available through automated reports, online dashboards, and calls



Personalized and prompt follow-up on alerts by our licensed registered nurses



Education on CLOZARIL® to help facilitate a better understanding of its use, potential therapeutic implications, and patient management



Consulting services for helping with complex cases




Facilitating the transition of patients within the community and from province to province by helping to find laboratories and pharmacies near their residence



Travel assistance service



Benign ethnic neutropenia (BEN) protocol



Committed to offering more to meet your expectations

CSAN® also provides:



Continuity of data throughout the patient journey



CSAN Patient Care Portal®:

- An interactive patient care portal
- Offers the treatment team several customizable options to help manage patient care records
 - » Designed to bring together in real time, relevant clinical information to assist prescribers in managing the requirements for their CLOZARIL® patients
- Maintains a history of each patient
- Customizable portal innovates how patients are enrolled and monitored with CSAN®:
 - Critical notices can be sent via SMS alerts and fax
 - E-signatures
 - Access to download an enrollment form



Learning Modules

- Accredited medical education
- Online training resources
- Webinars with specialists regarding clinical considerations for patients on CLOZARIL®

Canadian Schizophrenia Guidelines recommendations

The Canadian Schizophrenia Guidelines cite that established guidelines have identified clozapine as the only indicated treatment in treatment-resistant schizophrenia (TRS).⁴

Recommendation 1:	Recommendation 2:
Clozapine should be offered to patients who have TRS. (Grade A)*	Clozapine should be considered for patients whose schizophrenia has not responded to 2 antipsychotics. (Grade B)†

Please refer to the Canadian Schizophrenia Guidelines for complete information.

CSAN® aims to streamline the hematological monitoring of patients on CLOZARIL®

The CSAN® program week-over-week key performance index, has an annual average of over 90% compliance in supporting patients’ blood testing requirements.³

CLOZARIL® is available only through the CSAN® distribution system that ensures weekly, every-two-week or every-four-week hematological testing prior to the dispensing of the next period’s supply of CLOZARIL®.²

- CSAN® offers a **capillary point-of-care device** that generates results in real-time and simultaneously auto-uploads them to the patient’s CSAN® profile.
- To help simplify routine hematological monitoring required for patients treated with CLOZARIL®, CSAN® Pronto® offers onsite testing and can generate white blood cell counts/neutrophil percentage from a drop of capillary-drawn blood.
- Results are automatically uploaded into the CSAN Patient Care Portal® and made available to the healthcare team within minutes for added convenience.

*Grade A: At least one meta-analysis, systematic review, or randomized controlled trial rated as “1++” and directly applicable to the target population or a body of evidence consisting principally of studies rated as “1+”, being directly applicable to the target population, and demonstrating overall consistency of results.

†Grade B: A body of evidence including studies rated as “2++”, being directly applicable to the target population, and demonstrating overall consistency of results or extrapolated evidence from studies rated as 1++ or 1+.

1++: High-quality meta-analyses, systematic reviews of randomized controlled trials, or randomized controlled trials with a very low risk of bias.

1+: Well-conducted meta-analyses, systematic reviews, or randomized controlled trials with a low risk of bias.

2++: High-quality systematic reviews of case control or cohort studies or high-quality case control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal.

Offering CLOZARIL® monitoring in Canada

30 YEARS and counting

1991

Re-launch of CLOZARIL®

2004

CSAN® introduces the **Lablink system**:

- Creation of the CSAN Patient Care Portal®
- Same-day receipt of blood test results from the lab to the CSAN Patient Care Portal®
- Facilitates continuity of care through automatic generation of blood test confirmations to the pharmacy by fax

2018

Canadian manufactured since 2018

2019

HLS Therapeutics adds CSAN® Pronto®, a capillary point-of-care device that generates results in real-time and simultaneously auto-uploads them to the patient's CSAN® profile

For patients treated with CLOZARIL®


The CSAN® program aims to go beyond to help in patient management



*BEN: benign ethnic neutropenia

Start accessing the CSAN Patient Care Portal[®]

Download the CSAN[®] form here
to enroll your patients >>>>>>>>>>



For more information, please
contact CSAN[®] at 1-800-267-2726

References:

1. HLS Therapeutics data on file.
2. CLOZARIL[®] Product Monograph. HLS Therapeutics Inc. May 31, 2022.
3. HLS Therapeutics data on file.
4. Remington G, *et al.* Guidelines for the pharmacotherapy of schizophrenia in adults. *Can J Psychiatry.* 2017;62(9):604-616.



HLS Therapeutics Inc.

10 Carlson Court, Suite 701
Etobicoke, Ontario M9W 6L2
www.hlstherapeutics.com



CLOZARIL[®], CSAN[®] and CSAN[®] Patient Care Portal + Design are all registered trademarks of Novartis AG. Pronto[®] is a registered trademark of HLS Therapeutics Inc. HLS Therapeutics and the Tree design are registered trademarks of HLS Therapeutics Inc. All rights reserved.
© 2024 HLS Therapeutics Inc.

January 2024 CA-CL-00107-EN